Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
237.4 CHF | -2.51% |
|
-0.47% | -8.62% |
25/06 | Halozyme Therapeutics Says Roche's OCREVUS SC With ENHANZE Gets European Commission Approval | MT |
25/06 | Roche: approval of Ocrevus SC in Europe | CF |